Biohaven announces preliminary 4q2021 and full year net product revenue for nurtec odt, market leading novel migraine therapy

New haven, conn., jan. 6, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.

BHVN Ratings Summary

BHVN Quant Ranking